Actively Recruiting

Age: 18Years - 100Years
All Genders
NCT05157581

Extracorporeal Photopheresis in Sezary Syndrome

Led by Oleg E. Akilov, MD, PhD · Updated on 2025-12-30

20

Participants Needed

3

Research Sites

295 weeks

Total Duration

On this page

Sponsors

O

Oleg E. Akilov, MD, PhD

Lead Sponsor

T

Therakos

Collaborating Sponsor

AI-Summary

What this Trial Is About

The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).

CONDITIONS

Official Title

Extracorporeal Photopheresis in Sezary Syndrome

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Established diagnosis of Sezary syndrome (stage IVA1)
  • Amenable to extracorporeal photopheresis (ECP)
  • Minimum wash-out period of 3 weeks since last systemic therapy
  • Recovery from all adverse events related to prior therapy to grade 1 or less
  • Signed informed consent before any protocol-specific procedures
Not Eligible

You will not qualify if you...

  • Presence of visceral metastasis of lymphoma
  • Receiving radiotherapy or systemic anti-cancer therapy during the study
  • Active systemic or skin infections of grade 3 or higher severity
  • Serious medical conditions that impair ability to receive or tolerate treatment or comply with protocol
  • Dementia or altered mental status preventing informed consent
  • Known allergy to methoxsalen or heparin
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Emory University School of Medicine

Atlanta, Georgia, United States, 30322

Not Yet Recruiting

2

Cutaneous Translational Research Program - Johns Hopkins Medicine

Baltimore, Maryland, United States, 21287

Actively Recruiting

3

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

Loading map...

Research Team

C

Charity Ruhl, LPN

CONTACT

N

Nicolena Verardi, PA-C

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here